Angiotensin converting enzyme gene polymorphism and myocardial infarction a large association and linkage study

Holmer, Stephan; Bickeböller, Heike; Hengstenberg, Christian; Rohlmann, Friederike; Engel, Susanne; Löwel, Hannelore; Mayer, Björn; Erdmann, Jeanette; Baier, Christian; Klein, G.; Riegger, Günter A.J.; Schunkert, Heribert

doi:10.1016/s1357-2725(02)00261-3

Cited by 19 publications

(15 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The ACE Ins/Del polymorphism has been correlated with variations in ACE activity and blood pressure, and risks for myocardial infarction and other cardiovascular disorders (10,11,(38)(39)(40). However, other studies have failed to demonstrate such associations in different populations (14)(15)(16)41). These discrepant results may be related to the different ethnic origins of the studied groups.…”

Section: Discussionmentioning

confidence: 99%

Five polymorphisms in gene candidates for cardiovascular disease in Afro‐Brazilian individuals

Sakuma

Hirata

2004

Clinical Laboratory Analysis

View full text Add to dashboard Cite

Associations of polymorphisms in the angiotensin I-converting enzyme (ACE), apolipoprotein B (APOB) and apolipoprotein E (APOE) genes with hypertension and variations in lipid serum levels were evaluated in 184 Afro-Brazilians with a familial history of coronary artery disease (CAD). ACE (Ins/Del) and APOB (Ins/Del, XbaI, and EcoRI) and APOE (HhaI) polymorphisms were determined by polymerase chain reaction (PCR) and restriction fragment length polymorphism (RFLP) analyses on agarose, and polyacrylamide gel electrophoresis. Serum lipids were measured by means of routine enzymatic assays. The results showed a high frequency of hypertension (44%) in Afro-Brazilians that was increased in subjects >40 years old and those with a blood mass index (BMI) higher than 25 kg/m(2) (P<0.001). The ACE Del allele was associated with hypertension in men >40 years old (P<0.05). APOE (HhaI) and APOB (XbaI and Ins/Del) polymorphisms were not associated with hypertension or variations in serum concentrations of lipids, while subjects with the APOB E- allele had higher low-density lipoprotein cholesterol (LDL-C) levels than E+ carriers (P<0.05). These results suggest that ACE Ins/Del polymorphism is associated with hypertension, and APOB EcoRI polymorphism is associated with LDL-C variation in Afro-Brazilians.

show abstract

Section: Discussionmentioning

confidence: 99%

Five polymorphisms in gene candidates for cardiovascular disease in Afro‐Brazilian individuals

Sakuma

Hirata

2004

Clinical Laboratory Analysis

View full text Add to dashboard Cite

show abstract

“…In a large prospective study, the initial observation could not be confirmed [62]. Moreover, there was no statistically significant difference of the I/ D allelic frequencies between 1319 myocardial infarction patients and 2381 population-based controls from the MON-ICA study [63] and a meta-analysis could show that with increasing sample sizes, the odds ratios for the overall risk of myocardial infraction in dependence of the ACE genotype approach a value of 1 [64].…”

Section: The Renin -Angiotensin -Aldosterone Systemmentioning

confidence: 90%

Pharmacogenomics of heart failure - focus on drug disposition and action*1

Cascorbi¹,

Paul

Kroemer³

2004

Cardiovascular Research

View full text Add to dashboard Cite

Heart failure represents the composite endpoint of various cardiovascular disorders. Advanced pharmacotherapy resulted in significant improvement of overall survival, however with highly variable outcome, possibly due to genetic modification of drug disposition and action. This review highlights the role of genetic polymorphisms in systems responsible for disposition of drugs, used in heart failure patients (e.g. the polymorphic drug metabolizing enzymes such as cytochrome P450 enzymes, as well as polymorphic ATP-membrane transporters like P-glycoprotein (P-gp)). In addition, genetic variants in physiological systems, being target of drug action, particularly beta-adrenergic receptors, the renin-angiotensin-aldosterone system (RAAS)- and endothelin system, and the endothelial nitrogene monoxide (NO) synthase are reviewed. The current situation in pharmacogenomics of heart failure with respect to drug disposition and action is characterized by multiple studies investigating single components of a complex system. Therefore, overall conclusions regarding treatment and/or outcome of heart failure patients based on individual genetic traits require large prospective trials allowing for simultaneous assessment of multiple genetic variants in different systems. Using advanced screening technologies, such trials can be carried out in the near future.

show abstract

“…It is known that the D/I allele frequencies vary between populations with different genetic and environmental backgrounds. In fact, the frequency of the D allele in normal Caucasian is 50-58% [25,26], in normal Chinese is 35-39% [27] and 61-67% in Italian controls [24]. Therefore, it is important to extend the association study between the D/I ACE gene polymorphism to different populations to gain significant contributions to the pathogenesis of PD.…”

Section: Discussionmentioning

confidence: 99%

Genetic polymorphism of Angiotensin-Converting Enzyme is not associated with the development of Parkinson's disease and of l-dopa-induced adverse effects

Pascale

Purcaro

Passarelli

et al. 2009

Journal of the Neurological Sciences

View full text Add to dashboard Cite

Angiotensin converting enzyme gene polymorphism and myocardial infarction a large association and linkage study

Cited by 19 publications

References 24 publications

Five polymorphisms in gene candidates for cardiovascular disease in Afro‐Brazilian individuals

Five polymorphisms in gene candidates for cardiovascular disease in Afro‐Brazilian individuals

Pharmacogenomics of heart failure - focus on drug disposition and action*1

Genetic polymorphism of Angiotensin-Converting Enzyme is not associated with the development of Parkinson's disease and of l-dopa-induced adverse effects

Contact Info

Product

Resources

About